The FDA granted accelerated approval to Atezolizumab (Tecentriq) plus nanoparticle albumin-bound (nab) Paclitaxel (Abraxane) for unresectable locally advanced or metastatic PDL-1 positive triple negative breast cancer patients (Read more).

The FDA approved Atezolizumab (Tecentriq) in combination with Carboplatin and Etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer (Read more).

As per a recent clinical trial, Lorlatinib showed greater efficacy in patients with versus without Anaplastic lymphoma kinase (ALK) resistance mutations among patients with advanced ALK-positive non–small cell lung cancer (NSCLC) in whom one or more second-generation ALK tyrosine kinase inhibitors failed (Read more).

In another clinical trial, high Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI)affected overall survival in patients receiving first line chemotherapy plus Bevacizumab or Cetuximab for metastatic colorectal cancer (Read more). High tumor Mutation Burden (TMB) was found to be associated with improved overall survival and a high microsatellite Instability (MSI) showed better survival in Bevacizumab group compared to Cetuximab group.

In a study of 57 patients with HER2 amplified metastatic colorectal cancer, a 32% response rate was observed when the patients were treated with a combination of Pertuzumab and Trastuzumab (Read more).

Findings from a phase III clinical trial demonstrated better outcomes in refractory metastatic renal cell carcinoma patients (mRCC) when treated with Tivozanib compared to Sorafenib. Tivozanib treated patients had a higher progression-free survival (18% vs 5%) and objective response rate (18% vs 8%) compared to Sorafenib recipients (Read more).

Results from a retrospective cohort study showed evidence of activity of Cabozantinib in advanced non-clear cell renal carcinoma. Objective response was observed in 27% of patients. (Read more).

Phase 1b/II clinical trial showed a higher response rate in previously untreated older Acute myeloid leukemia patients when treated with a combination of Venetoclax and low-dose Cytarabine, who were ineligible for intensive chemotherapy (Read more).

In another phase III clinical trial study, first line treatment of indolent non-Hodgkin lymphoma or mantle cell lymphoma patients with Bendamustine/Rituximab showed better outcomes compared  to treatment with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CVP (rituximab plus cyclophosphamide, vincristine, and prednisone) (Read more).